Generic Trintellix ( Vortioxetine )

Order cheap Generic Trintellix (Vortioxetine) without dr prescription in the United States

In our USA pharmacy, you can buy Trintellix without a prescription, with delivery across the USA within 2‑5 days. Discreet and anonymous packaging.
Trintellix (vortioxetine) is a multimodal antidepressant that works by inhibiting serotonin reuptake and modulating multiple serotonin receptors. It combines serotonin transporter (SERT) inhibition with 5‑HT1A agonism, 5‑HT1B partial agonism, and antagonism at 5‑HT3, 5‑HT1D, and 5‑HT7 receptors, a unique profile thought to enhance serotonergic neurotransmission, improve mood, and potentially benefit cognitive function.
Usual adult dose: The recommended starting dose is 10 mg once daily, taken with or without food. The dose may be increased to 20 mg once daily or decreased to 5 mg once daily based on individual response and tolerability. The maximum recommended dose is 20 mg once daily.
Dosage form: Immediate‑release film‑coated tablets (5 mg, 10 mg, 20 mg).
Onset of action: Some patients may experience initial improvement within 2 weeks; the full antidepressant effect typically develops over 4‑8 weeks or longer.
Duration of action: Once‑daily dosing provides 24‑hour coverage due to a prolonged terminal half‑life of approximately 66 hours.
Alcohol consumption should be limited or avoided; concomitant use may increase the risk of central nervous system depression, worsen depressive symptoms, and exacerbate potential adverse effects such as nausea and dizziness.
Most common side effects: nausea, diarrhea, dry mouth, constipation, vomiting, dizziness, and abnormal dreams (incidence ≥5% and at least twice that of placebo).
Would you like to try Trintellix without a prescription?

General Information about Trintellix

• INN (International Nonproprietary Name): Vortioxetine
• Brand names available in the USA: Trintellix® (Takeda Pharmaceuticals U.S.A., Inc. and H. Lundbeck A/S). Generic vortioxetine tablets are available from several FDA‑approved manufacturers, including Accord Healthcare, Inc., Alembic Pharmaceuticals, Teva Pharmaceuticals USA, Inc., and others.
• ATC code: N06AX26
• Dosage forms and strengths: Film‑coated immediate‑release tablets: 5 mg, 10 mg, and 20 mg.
• Manufacturers in USA: Takeda Pharmaceuticals U.S.A., Inc. (brand Trintellix®); generic manufacturers include Accord Healthcare, Inc., Alembic Pharmaceuticals, Teva Pharmaceuticals USA, Inc., and other authorized companies.
• Registration status in USA: Approved by the U.S. Food and Drug Administration (FDA) on September 30, 2013 (NDA 204447).
• OTC / Rx classification: Prescription only (Rx). DEA Schedule: None.

Mechanism of Action and Pharmacology

Vortioxetine is classified as a serotonin (5‑HT) modulator and stimulator, a novel multimodal antidepressant. Its therapeutic effect is derived from two complementary pharmacological actions: direct inhibition of the serotonin transporter (SERT) and modulation of serotonin receptor subtypes. By blocking SERT, vortioxetine increases extracellular serotonin levels in a manner similar to SSRIs. Additionally, it acts as a high‑affinity agonist at the 5‑HT1A receptor, a partial agonist at the 5‑HT1B receptor, and a potent antagonist at 5‑HT3, 5‑HT1D, and 5‑HT7 receptors. This receptor profile is believed to enhance serotonergic neurotransmission at postsynaptic sites, promote dopamine and norepinephrine release in certain brain regions, and potentially mitigate the gastrointestinal side effects associated with pure 5‑HT3 stimulation. Preclinical studies suggest that the 5‑HT3 antagonism may reduce nausea while the 5‑HT1A agonism may alleviate sexual dysfunction, offering a tolerability advantage over conventional SSRIs. Vortioxetine is slowly absorbed, with peak plasma concentrations reached 7‑11 hours after oral dosing; bioavailability is approximately 75% and is not significantly affected by food. It is extensively metabolized by CYP2D6 and CYP3A4/5, followed by glucuronidation. The elimination half‑life is approximately 66 hours, enabling once‑daily dosing, and steady‑state is reached in about 2 weeks. Plasma protein binding is high (98‑99%).

Indications

• Treatment of major depressive disorder (MDD) in adults.
• Off‑label uses (not FDA‑approved): Generalized anxiety disorder (clinical trials have shown positive results), cognitive dysfunction associated with depression, and treatment of depressive symptoms in older adults.

Important Warnings and Precautions

TRINTELLIX CARRIES A BOXED WARNING FOR SUICIDAL THOUGHTS AND BEHAVIORS. Antidepressants, including vortioxetine, increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (ages 18‑24) during initial treatment. Closely monitor all antidepressant‑treated patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the first few months of therapy and at times of dose changes. Trintellix is not approved for use in pediatric patients. Serotonin syndrome, a potentially life‑threatening condition, may occur with vortioxetine, particularly when used concomitantly with other serotonergic agents (SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's Wort) but also when taken alone. Symptoms include mental status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. Discontinue vortioxetine and initiate supportive treatment if serotonin syndrome occurs. Vortioxetine may increase the risk of bleeding events, especially when co‑administered with aspirin, NSAIDs, warfarin, or other anticoagulants/antiplatelet agents. Activation of mania or hypomania may occur; screen patients for bipolar disorder and personal/family history of mania prior to initiating therapy. Discontinuation syndrome (dysphoric mood, irritability, agitation, dizziness, sensory disturbances, confusion, headache, insomnia) may occur upon abrupt cessation; gradual dose reduction is recommended when discontinuing therapy. Vortioxetine may cause mydriasis and should be used with caution in patients with increased intraocular pressure or those with untreated anatomically narrow angles (angle‑closure glaucoma). Hyponatremia, possibly due to SIADH, has been reported; caution is advised in elderly patients and those who are volume‑depleted or taking diuretics. Seizures have been reported; use with caution in patients with a history of seizure disorder.

At‑risk groups

• Elderly: No dose adjustment is required based solely on age. However, elderly patients may be at increased risk of hyponatremia and bleeding; monitor closely. Clinical studies included patients 65 years and older, but no overall differences in safety or efficacy were observed.
• Pregnancy: There are no adequate and well‑controlled studies in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants exposed to serotonergic antidepressants late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Pregnant women exposed to vortioxetine are encouraged to enroll in the National Pregnancy Registry for Antidepressants.
• Breastfeeding: Vortioxetine is present in human milk. Because of the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment. A decision should be made whether to discontinue nursing or discontinue the drug.
• Renal impairment: No dose adjustment is required in patients with mild, moderate, or severe renal impairment. Vortioxetine has not been studied in patients with end‑stage renal disease (ESRD).
• Hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment (Child‑Pugh A or B). Vortioxetine has not been studied in patients with severe hepatic impairment (Child‑Pugh C); use with caution.
• Pediatric: Safety and efficacy have not been established in pediatric patients. Trintellix is not approved for use in individuals under 18 years of age.
• Bipolar disorder: Screen for personal or family history of bipolar disorder, mania, or hypomania before initiating treatment.
• Seizure disorders: Use with caution in patients with a history of seizures or conditions that lower the seizure threshold.
• CYP2D6 poor metabolizers: Although no specific dose adjustment is recommended, patients who are CYP2D6 poor metabolizers have approximately twice the vortioxetine exposure; initiate at the recommended starting dose of 10 mg once daily and monitor closely for adverse effects.

Driving and alcohol

Vortioxetine may impair judgment, thinking, and motor skills. Patients should exercise caution when driving or operating hazardous machinery until they have gained sufficient experience with the drug to determine its effect on their cognitive and motor performance. Alcohol consumption should be limited or avoided entirely during treatment. Alcohol may worsen depressive symptoms, potentiate central nervous system depression, impair cognitive and motor function, and increase the risk of gastrointestinal side effects (particularly nausea and dizziness). Heavy alcohol intake, especially in combination with vortioxetine, may also increase the risk of hepatic injury.

Dosage Instructions

• Recommended initial dose: 10 mg orally once daily with or without food.
• Dose titration: Based on clinical response and tolerability, the dose may be increased to 20 mg once daily or decreased to 5 mg once daily. The minimum effective dose is 5 mg once daily; the maximum recommended dose is 20 mg once daily. Allow at least 1‑2 weeks between dose adjustments to assess response.
• Administration: Tablets can be taken with or without food. Swallow whole; do not crush or chew.
• Missed dose: If a dose is missed, take it as soon as remembered. If it is almost time for the next dose, skip the missed dose and resume the regular schedule. Do not double doses.
• Dose adjustment with strong CYP2D6 inhibitors: When co‑administered with strong CYP2D6 inhibitors (e.g., bupropion, fluoxetine, paroxetine, quinidine), reduce the vortioxetine dose by half (e.g., 5 mg once daily if the original dose was 10 mg; 10 mg once daily if the original dose was 20 mg). The original dose may be resumed when the CYP2D6 inhibitor is discontinued.
• Dose adjustment with strong CYP inducers: When co‑administered with strong CYP inducers (e.g., rifampin, carbamazepine, phenytoin) for more than 14 days, consider increasing the vortioxetine dose up to 2‑fold, to a maximum of 30 mg once daily, based on clinical response. Gradually reduce the dose to the original level over 1‑2 weeks when the inducer is discontinued.
• Discontinuation: Gradually reduce the dose whenever possible to minimize discontinuation symptoms. A typical taper might reduce by 5 mg every 1‑2 weeks.
• Switching to or from MAOIs: At least 14 days must elapse between discontinuation of an MAOI antidepressant and initiation of vortioxetine, and at least 14 days between stopping vortioxetine and starting an MAOI.

Side Effects and Contraindications

Most common adverse reactions (incidence ≥5% and at least twice the rate of placebo): Nausea (21‑32%), diarrhea (7‑10%), dry mouth (6‑8%), constipation (3‑6%), vomiting (3‑6%), dizziness (4‑9%), and abnormal dreams (2‑4%). Nausea is dose‑dependent, most prominent during the first week of therapy, and tends to diminish with continued treatment.
Other common adverse reactions: Pruritus, fatigue, decreased appetite, weight gain, and sexual dysfunction (decreased libido, erectile dysfunction, delayed ejaculation). Sexual dysfunction rates are generally comparable to other SSRIs/SNRIs, though some studies suggest a slightly lower incidence.
Serious adverse reactions: Serotonin syndrome, suicidal thoughts and behaviors (especially in young adults), activation of mania/hypomania, clinically significant bleeding events, hyponatremia, seizures, and angle‑closure glaucoma. Rare postmarketing reports include pancreatitis, urinary retention, and severe hepatic injury.
Absolute contraindications: Concomitant use of monoamine oxidase inhibitors (MAOIs), including linezolid and intravenous methylene blue, or use within 14 days of stopping MAOIs, due to increased risk of serotonin syndrome. Known hypersensitivity to vortioxetine or any excipient.

Drug Interactions

• Monoamine oxidase inhibitors (MAOIs): Contraindicated. Concomitant use significantly increases the risk of serotonin syndrome. Separate use by at least 14 days.
• Other serotonergic drugs (e.g., SSRIs, SNRIs, triptans, tricyclic antidepressants, opioids including fentanyl, lithium, buspirone, amphetamines, tryptophan, and St. John's Wort): Increased risk of serotonin syndrome. Monitor carefully; if serotonin syndrome occurs, discontinue vortioxetine and/or the concomitant serotonergic agent.
• Strong CYP2D6 inhibitors (e.g., bupropion, fluoxetine, paroxetine, quinidine): Significantly increase vortioxetine exposure. Reduce vortioxetine dose by half during co‑administration.
• Strong CYP inducers (e.g., rifampin, carbamazepine, phenytoin): Decrease vortioxetine exposure. Consider increasing vortioxetine dose up to 2‑fold (maximum 30 mg/day) when used for more than 14 days.
• Antiplatelet agents and anticoagulants (e.g., aspirin, NSAIDs, clopidogrel, warfarin, heparin, DOACs): Serotonin release by platelets plays an important role in hemostasis. Concomitant use may increase the risk of bleeding. Carefully monitor INR in patients taking warfarin.
• Alcohol: May worsen depressive symptoms, impair cognitive and motor function, and exacerbate gastrointestinal adverse effects. Limited or avoided use is recommended.
• Vortioxetine does not meaningfully alter the pharmacokinetics of cytochrome P450 substrates at clinical doses, though caution is advised with narrow therapeutic index drugs metabolized by CYP2D6.

Practical Advice

• Take Trintellix exactly as prescribed, once daily with or without food. Consistency is more important than the timing of the dose relative to meals.
• Do not stop taking Trintellix abruptly. Gradual dose reduction over several weeks is recommended to minimize the risk of discontinuation symptoms.
• If a dose is missed, take it as soon as you remember on the same day. If it is almost time for the next dose, skip the missed dose and resume the normal schedule. Do not double doses.
• Monitor for signs of clinical worsening, suicidality, or unusual changes in behavior, especially during the first few months of therapy or at times of dose changes. Family members and caregivers should be alert to such changes and communicate them to the healthcare provider.
• Watch for symptoms of serotonin syndrome: agitation, confusion, hallucinations, rapid heart rate, fluctuating blood pressure, fever, excessive sweating, shivering, muscle stiffness, twitching, loss of coordination, nausea, vomiting, and diarrhea. Seek immediate medical attention if these occur.
• Inform all healthcare providers (including dentists and surgeons) that you are taking vortioxetine, especially before any surgical procedure, because of the increased bleeding risk.
• Use caution when driving or operating machinery until you know how vortioxetine affects you; it may impair cognitive and motor performance.
• Avoid or limit alcohol consumption during treatment.
• Store at room temperature (20‑25°C / 68‑77°F) with excursions permitted between 15‑30°C (59‑86°F). Keep in the original container, out of reach of children.
• Attend all scheduled follow‑up appointments. Regular monitoring of mood, response to treatment, and potential adverse effects is essential for safe and effective therapy.

Alternative Medications

• Vilazodone (Viibryd®): A serotonin partial agonist and reuptake inhibitor (SPARI) with 5‑HT1A partial agonism and SERT inhibition. Also indicated for MDD.
• Selective serotonin reuptake inhibitors (SSRIs): Escitalopram (Lexapro®), sertraline (Zoloft®), fluoxetine (Prozac®), paroxetine (Paxil®), citalopram (Celexa®). Well‑established first‑line antidepressants with broad clinical experience.
• Serotonin‑norepinephrine reuptake inhibitors (SNRIs): Venlafaxine (Effexor XR®), desvenlafaxine (Pristiq®), duloxetine (Cymbalta®), levomilnacipran (Fetzima®). Duloxetine is also indicated for neuropathic pain and fibromyalgia.
• Bupropion (Wellbutrin XL®, Wellbutrin SR®): An aminoketone antidepressant with noradrenergic and dopaminergic activity. Favorable sexual side‑effect profile; also used for smoking cessation.
• Mirtazapine (Remeron®): A tetracyclic antidepressant with alpha‑2 adrenergic antagonist and 5‑HT2/5‑HT3 antagonist activity. Associated with sedation and weight gain.
• Trazodone (Desyrel®): A serotonin antagonist and reuptake inhibitor (SARI); commonly used at lower doses for insomnia and at higher doses for depression.
• Esketamine (Spravato®): A rapid‑acting NMDA receptor antagonist, approved for treatment‑resistant depression; administered as a nasal spray under supervision.

Clinical Efficacy

The efficacy of Trintellix for the treatment of major depressive disorder was established in six short‑term (6‑8 week) randomized, double‑blind, placebo‑controlled, fixed‑dose trials in adult outpatients who met DSM‑IV‑TR criteria for MDD. Vortioxetine 5 mg, 10 mg, and 20 mg once daily demonstrated statistically significant superiority over placebo on the primary endpoint, the change from baseline to endpoint in the Montgomery‑Åsberg Depression Rating Scale (MADRS) total score. Placebo‑subtracted differences in MADRS score ranged from approximately ‑2.0 to ‑5.5 points across studies and doses. Additional secondary endpoints, including Clinical Global Impression (CGI) improvement and response rates (≥50% reduction in MADRS), were also significantly improved. A long‑term maintenance study demonstrated that vortioxetine significantly delayed time to relapse compared with placebo over a 24‑to 64‑week period. Notably, in a dedicated cognition study (FOCUS), vortioxetine 10 mg and 20 mg significantly improved cognitive function, as assessed by the Digit Symbol Substitution Test (DSST) and other neuropsychological tests, independent of its mood effects in adults with MDD. The cognitive benefits are thought to be related to its multimodal receptor activity. Across clinical trials, vortioxetine was well‑tolerated, with nausea being the most common adverse event, and rates of sexual dysfunction and weight gain were generally comparable to or lower than those observed with SSRIs/SNRIs.

Important:

Trintellix (vortioxetine) is a prescription antidepressant that must be used under the supervision of a qualified healthcare provider. A comprehensive psychiatric evaluation, including screening for bipolar disorder and assessment of suicide risk, is necessary before initiating treatment. Antidepressants, including Trintellix, increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (ages 18‑24) with major depressive disorder and other psychiatric conditions. Closely monitor all patients for clinical worsening, suicidality, or unusual changes in behavior, especially during the initial few months of therapy and at times of dose adjustments. Trintellix is not approved for use in pediatric patients. Serotonin syndrome is a potentially life‑threatening condition; seek immediate medical attention if symptoms such as agitation, hallucinations, confusion, rapid heart rate, fever, muscle stiffness, or seizures develop. Do not use Trintellix with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOI therapy. Trintellix may increase the risk of bleeding, particularly when used with aspirin, NSAIDs, warfarin, or other medications that affect coagulation. Avoid abrupt discontinuation; the dose should be gradually tapered to minimize withdrawal symptoms. Alcohol should be limited or avoided during treatment. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the potential risks and benefits with their healthcare provider. Keep out of reach of children and never share this medication with others.

How to buy Generic Trintellix no prescription U.S. Online Pharmacy